Cardinal Capital Management Has $1.39 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Cardinal Capital Management boosted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,499 shares of the specialty pharmaceutical company’s stock after buying an additional 431 shares during the quarter. Cardinal Capital Management’s holdings in Jazz Pharmaceuticals were worth $1,393,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of JAZZ. Capital World Investors acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at about $171,943,000. Swedbank AB bought a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $106,936,000. Rubric Capital Management LP acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at approximately $65,812,000. Pacer Advisors Inc. increased its position in Jazz Pharmaceuticals by 40.7% in the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after buying an additional 527,187 shares during the period. Finally, Baupost Group LLC MA increased its position in Jazz Pharmaceuticals by 52.8% in the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after buying an additional 440,552 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insider Activity

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $115.04 on Friday. The firm has a market capitalization of $7.25 billion, a P/E ratio of 23.72, a P/E/G ratio of 1.34 and a beta of 0.57. The stock has a fifty day moving average price of $110.88 and a two-hundred day moving average price of $109.79. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $137.38. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. As a group, analysts anticipate that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

JAZZ has been the topic of several research analyst reports. UBS Group lowered their price objective on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Wells Fargo & Company cut their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st. Piper Sandler decreased their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $205.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $173.14.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.